At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 28 enrolled

Drug / intervention

TAS 102drug

Likely dose

TAS 102 35 mg/m2from record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04923529

NCT04923529Phase 2Completed

Compare CT.gov

Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

The University of Hong Kong·interventional·Posted Jun 11, 2021·Updated Jul 18, 2025

In Brief

A Phase 2 clinical trial evaluating TAS 102 for Pancreas Cancer. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This is a prospective phase II, single arm clinical trial conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of TAS-102 in advanced or metastatic pancreatic cancer patients.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsPancreas Cancer

CountriesHong Kong

CollaboratorsTaiho Pharmaceutical Co., Ltd.

Timeline

Phase 2CompletedFinished

20222023202420252026

Enrollment StartMar 2021

First PostedJun 2021

Primary CompletionMar 2024

Study CompletionDec 2024

TodayJul 2026

First PostedJun 11, 2021

Enrollment StartMar 1, 2021

Primary CompletionMar 25, 2024

Study CompletionDec 31, 2024

TodayJul 2, 2026

Enrollment to primary: 3.1 yearsPosted 5.1 years ago

Interventions

TAS 102drug

Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. Days 6 through 7: Recovery Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12. Days 13 through 28: Recovery